CD274 and neoplasm: Programmed death-ligand 1 (PD-L1), tumor mutation burden (TMB), microsatellite instability (MSI), and deficient mismatch repair system (dMMR) have emerged as the most studied biomarkers, but the predictive capabilities of each biomarker are different, and there are significant limitations to their use.